Vol.

No.

January 07, 2022Jan 07, 2022

DOWNLOAD THE PDF

The Cancer Letter’s roadmap for reporting harassment Panel of experts responds to questions from women in oncology

Cover Story

Free

The Cancer Letter’s roadmap for reporting harassment

Panel of experts responds to questions from women in oncology

By Alice Tracey

After consulting with women in oncology, The Cancer Letter has created a guide to help whistleblowers think strategically as they report gender bias and confront institutional resistance.

Conversation with The Cancer Letter COVID-19 & Cancer Free

Northwell’s Barakat on the omicron wave: Hospitalizations spike, but not as many need ICU

By Paul Goldberg

UChicago oncologist settles SEC charges, pleads not guilty to criminal insider trading

By Alice Tracey

Guest Editorial

Symposium focuses on racism in health care and public health—from Nazi medicine to COVID and cancer

By Arthur L. Caplan

Free Obituary

Beatrice Mintz, PhD, pioneering researcher at Fox Chase, dies at 100

By Jonathan Chernoff

Free In the Archives

NCI, Bidens celebrate “decades of investment and innovation”

In Brief

Lynn M. Schuchter elected ASCO president for 2023-2024; seven members elected to ASCO board of directors and nominating committee

Karen L. Kelly named IASLC chief executive officer

Wendy Brewster named associate director of DEI at UNC Lineberger

Ramesh Narayanan named deputy director at UTHSC

Amit Maity to lead radiation oncology at Huntsman

Marshall Hospital partners with UC Davis Health

Danish Ahmad joins the Department of Medicine at Fox Chase

Fox Chase researchers to use $497K NCI grant to develop platform for testing pancreatic cancer drug therapies

Clinical Roundup

NCCN updates COVID-19 guidelines for cancer patients

OSU researchers find three-drug combo boosts immune system in stem cell transplantation

Receiving CAR T therapy sooner may improve lymphoma survival

Relatlimab + Opdivo improves PFS in metastatic melanoma

MD Anderson research links high-fiber diet to improved outcomes in melanoma

Drugs & Targets

FDA clears IND for P-MUC1C-ALLO1, a fully allogeneic CAR T targeting multiple solid tumors

FDA grants Breakthrough Therapy designation for CLN-081 in locally advanced or metastatic EGFR-mutated NSCLC

FDA grants Fast Track designation for Reqorsa with Keytruda in NSCLC

Rain Therapeutics, Roche to collaborate on clinical trial of milademetan combination with anti-PD-L1 immunotherapy for solid tumors

NCI Trials

NCI Trials for January 2022

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues